Lumos Diagnostics Secures US$317M Deal Ahead of FDA CLIA Waiver Decision March 31
Lumos Diagnostics Holdings Limited (ASX: LDX) has reported transformational progress in its first half financial results for FY26, headlined by the US$317 million Lumos Diagnostics FebriDx PHASE Agreement with PHASE Scientific and anticipation of a pivotal FDA CLIA waiver decision by 31 March 2026. The company achieved positive operating cash flow of $0.8 million, representing a $7.1 million improvement over the prior corresponding period, while securing 100% Medicare reimbursement recognition across all seven U.S. jurisdictions.
Lumos Diagnostics delivers pivotal milestones in first half as FebriDx CLIA waiver decision approaches
In its half-year report for the six months ended 31 December 2025, Lumos detailed a series of commercial and regulatory achievements that position the company at a critical inflection point ahead of anticipated FDA clearance for its FebriDx respiratory infection diagnostic test.
The Lumos Diagnostics FebriDx PHASE Agreement, valued at US$317 million (A$487 million), provides a six-year exclusive U.S. distribution pathway and validates the commercial potential of the FebriDx technology. The company has already received $3.5 million under the agreement, comprising a $1.0 million exclusivity fee, $1.0 million pre-paid purchase order on signing, and a further $1.5 million pre-paid purchase order following CLIA waiver submission.
An additional $5.0 million non-refundable prepayment will be triggered upon FDA CLIA waiver approval, expected by the end of Q1 CY26.
The company’s CLIA waiver submission to the FDA was completed in August 2025 following successful clinical study completion. After addressing FDA feedback through a supplementary usability assessment, all matters have been resolved and submitted. Management has stated the regulatory process remains on track with no substantive variation to previously communicated timelines.
Doug Ward, CEO
“We are extremely pleased with the financial results, momentum and milestones achieved during the first half of the financial year. From securing the transformational PHASE Scientific distribution agreement and advancing our BARDA supported CLIA waiver submission, to progressing the paediatric study and securing Medicare reimbursement coverage, the team has delivered strongly against the Company’s strategic plan as we prepare for CLIA Waiver.”
The achievement of 100% Medicare reimbursement recognition across all seven Medicare Administrative Contractor (MAC) jurisdictions significantly strengthens the foundation for broader U.S. adoption, with Medicare representing approximately 20-24% of the overall U.S. payor mix.
When big ASX news breaks, our subscribers know first
Understanding CLIA waiver and why it matters for FebriDx market access
CLIA waiver classification allows diagnostic tests to be performed in non-laboratory settings such as pharmacies, urgent care clinics, and physician offices without requiring certified laboratory facilities. This classification dramatically expands the addressable market for point-of-care diagnostics.
FebriDx differentiates bacterial from non-bacterial respiratory infections in approximately 10 minutes, supporting clinical decision-making and potentially reducing unnecessary antibiotic prescribing.
Without CLIA waiver, tests are restricted to certified laboratory environments, limiting accessibility and adoption. The waiver transforms FebriDx from a hospital-based product to one accessible across the entire U.S. primary care landscape, including retail pharmacies and general practice settings.
Doug Ward, CEO
“Looking ahead we remain laser focused on securing FDA CLIA waiver for FebriDx® within the coming month, executing our PHASE Scientific distribution agreement, continuing to drive reimbursement adoption, and completing the paediatric study to further expand the U.S. market opportunity.”
PHASE Scientific agreement valued at US$317 million validates FebriDx technology
The six-year exclusive U.S. distribution agreement with PHASE Scientific, announced 16 July 2025, provides commercial validation of the FebriDx platform and establishes a clear pathway to market following CLIA waiver approval.
The agreement features a milestone-based payment structure already generating cash for Lumos:
- $1.0 million exclusivity fee (received)
- $1.0 million pre-paid purchase order on signing (received)
- $1.5 million pre-paid purchase order on CLIA waiver submission (received)
- $5.0 million non-refundable prepayment on FDA CLIA waiver approval (pending)
Total payments received to date: $3.5 million
The agreement delivers near-term cash while positioning Lumos for substantial revenue generation post-clearance. The partnership provides commercial infrastructure and distribution capabilities without requiring significant capital investment from Lumos to establish independent U.S. market presence.
CLIA waiver submission progressing as expected
Clinical study completion and FDA submission occurred 18 August 2025. Following 90-day FDA feedback, Lumos completed a supplementary usability assessment over one day and updated usage instructions as recommended. All matters have been addressed and submitted to the FDA, with management maintaining expectations for a decision by 31 March 2026.
Paediatric study expands addressable market by 15-20%
The BARDA-funded paediatric study for patients aged 2-12 years commenced 22 October 2025 with first patient enrolment. The study is expected to enrol between 500-800 patients across approximately 20 sites over a 12-month period to achieve sufficient positive bacterial cases for analysis.
The Biomedical Advanced Research and Development Authority (BARDA) is supporting the paediatric study with $6.2 million in non-dilutive funding. Lumos has received $1.9 million in milestone payments to date, with Milestone 6 completed subsequent to period end based on enrolled patient numbers.
The paediatric indication is expected to expand the U.S. market opportunity for FebriDx by approximately 15-20%, addressing an important clinical segment with distinct diagnostic needs.
First half financial performance reflects strategic transition
Lumos recorded revenue of $6.12 million for 1H FY26 compared to $6.31 million in the prior corresponding period, with a shift in revenue mix toward FebriDx product sales. Services income generated $4.44 million (1H FY25: $5.47 million), while product sales contributed $1.68 million (1H FY25: $0.84 million).
FebriDx revenue grew by $1.39 million compared to the prior period, more than offsetting the $0.65 million decline from discontinued ViraDx product sales. Gross margin improved to 68% from 67% in the prior half despite the revenue mix change.
| Metric | 1H FY26 | 1H FY25 | Change |
|---|---|---|---|
| Total Revenue | $6.12m | $6.31m | -3% |
| FebriDx Revenue | $1.68m | $0.84m | +100% |
| Gross Margin | 68% | 67% | +1pp |
| Operating Cash Flow | +$0.76m | -$6.32m | +$7.1m |
| Net Loss | $4.88m | $2.80m | – |
The reduction in Services revenue of $1.03 million was primarily driven by lower revenue recognised from the Hologic IP Agreement as project timelines extended. During 1H FY25, Lumos recognised $2.60 million from the Hologic agreement compared to $1.00 million in 1H FY26, partially offset by $0.6 million from additional project work.
Other income of $2.46 million comprises receipts from BARDA supporting the FebriDx CLIA waiver and paediatric trials. These non-dilutive funds directly offset trial costs.
Total operating expenses increased to $8.00 million from $6.14 million in the prior period, driven by four primary factors: costs of running FebriDx CLIA waiver and paediatric trials, early-stage research on women’s health products, additional sales and marketing spend for FebriDx, and increased employee costs.
Adjusted EBITDA loss was $1.38 million compared to $0.94 million in the prior half. The net loss after tax of $4.88 million was primarily driven by non-cash items, including $0.80 million in finance costs associated with the A$5.0 million loan facility and $1.40 million in share-based payments expense.
Net operating cash flow turned positive at $0.76 million, representing a $7.08 million improvement over the prior corresponding period. The improvement was driven by higher receipts from customers and better alignment of BARDA receipts with trial expenditure.
Non-dilutive funding and balance sheet positioning
During 1H FY26, Lumos received $2.75 million from BARDA. Total non-dilutive funding since March 2023 has reached $13.4 million, including the Hologic sale and leaseback agreement and BARDA funding for FebriDx trials.
The company established an A$5.0 million loan facility to provide working capital through to anticipated CLIA waiver approval. Finance costs of $0.80 million relate to establishment and service fees, representing a non-cash charge tied to 15.0 million shares provided to lenders.
Services business delivers development milestones across key partnerships
The Hologic fFN diagnostic product development programme has progressed with expanded scope since the original agreement announced 11 January 2024. The scope has been expanded three times, including in August and November 2025, increasing total potential milestone payments to between $6.5-7.0 million from an initial $4.7 million.
Hologic is the sole global manufacturer of the on-market fFN diagnostic test for pre-term birth. Lumos is partnering to develop the next generation product, adapting the test for use on Lumos’ proprietary reader platform with enhanced connectivity capabilities. Project completion is estimated for February 2027.
The Aptatek Biosciences PheCheck development contract, announced 1 September 2025, advances an in-home PKU monitoring device. The initial $1.5 million time-and-materials contract covered design maturation, blood processing, reader development, and verification testing. Subsequent to period end, the agreement was extended by $0.4 million to include management of an IRB-approved multi-centre study commencing January 2026 with approximately 12-month duration.
Subject to successful study outcomes and FDA clearance, Lumos expects to pursue additional manufacturing and commercial opportunities with Aptatek.
The next major ASX story will hit our subscribers first
Near-term catalysts and outlook
The coming weeks represent a significant inflection point for Lumos, with several catalysts positioned to drive commercial acceleration:
- FDA CLIA waiver decision expected by 31 March 2026
- $5.0 million prepayment from PHASE Scientific upon clearance
- Implementation of PHASE Scientific distribution agreement and volume scale-up
- Continued paediatric study progress to expand addressable market by 15-20%
- Delivery of Hologic fFN development milestones
- Advancement of women’s health pipeline
Doug Ward, CEO
“Looking ahead we remain laser focused on securing FDA CLIA waiver for FebriDx® within the coming month, executing our PHASE Scientific distribution agreement, continuing to drive reimbursement adoption, and completing the paediatric study to further expand the U.S. market opportunity. At the same time, we remain committed to delivering key development milestones for our commercial partners and advancing our own women’s health pipeline, positioning Lumos for sustainable growth.”
With the CLIA waiver submission complete, reimbursement infrastructure established, and commercial partnership secured, FDA clearance would unlock immediate cash generation through the PHASE Scientific prepayment and position the company to scale FebriDx revenues across the U.S. primary care market.
Want the Next Biotech Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving biotech announcements delivered straight to your inbox the moment they drop.